Johnson Investment Counsel Inc. Has $8.43 Million Stock Position in Intuitive Surgical, Inc. (NASDAQ:ISRG)

Johnson Investment Counsel Inc. grew its stake in shares of Intuitive Surgical, Inc. (NASDAQ:ISRG) by 10.6% in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 24,650 shares of the medical equipment provider’s stock after acquiring an additional 2,357 shares during the period. Johnson Investment Counsel Inc.’s holdings in Intuitive Surgical were worth $8,429,000 at the end of the most recent quarter.

Other institutional investors also recently made changes to their positions in the company. Desjardins Global Asset Management Inc. boosted its stake in shares of Intuitive Surgical by 131.6% in the first quarter. Desjardins Global Asset Management Inc. now owns 2,552 shares of the medical equipment provider’s stock valued at $652,000 after buying an additional 1,450 shares during the period. Ritholtz Wealth Management boosted its stake in Intuitive Surgical by 12.6% in the second quarter. Ritholtz Wealth Management now owns 2,838 shares of the medical equipment provider’s stock valued at $970,000 after buying an additional 318 shares in the last quarter. Lion Street Advisors LLC bought a new position in Intuitive Surgical in the second quarter valued at about $374,000. Achmea Investment Management B.V. raised its stake in Intuitive Surgical by 179.8% during the second quarter. Achmea Investment Management B.V. now owns 17,471 shares of the medical equipment provider’s stock worth $5,974,000 after acquiring an additional 11,226 shares in the last quarter. Finally, Hutchens & Kramer Investment Management Group LLC bought a new position in shares of Intuitive Surgical in the second quarter worth about $212,000. Institutional investors own 82.91% of the company’s stock.

Wall Street Analyst Weigh In

Several brokerages recently commented on ISRG. JPMorgan Chase & Co. increased their price objective on shares of Intuitive Surgical from $335.00 to $365.00 and gave the company an “overweight” rating in a research note on Friday, July 21st. Morgan Stanley lowered their target price on Intuitive Surgical from $330.00 to $300.00 and set an “equal weight” rating for the company in a report on Monday, October 23rd. UBS Group cut their price target on Intuitive Surgical from $385.00 to $314.00 and set a “neutral” rating on the stock in a research note on Thursday, October 19th. Stifel Nicolaus upped their price objective on Intuitive Surgical from $315.00 to $350.00 and gave the company a “buy” rating in a research note on Friday. Finally, SVB Leerink started coverage on shares of Intuitive Surgical in a research report on Monday, October 16th. They set an “outperform” rating and a $342.00 target price on the stock. Five equities research analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the stock. According to data from MarketBeat.com, Intuitive Surgical presently has a consensus rating of “Moderate Buy” and a consensus target price of $342.71.

Insider Activity

In related news, CEO Gary S. Guthart sold 27,385 shares of Intuitive Surgical stock in a transaction on Thursday, October 26th. The shares were sold at an average price of $260.11, for a total value of $7,123,112.35. Following the completion of the sale, the chief executive officer now owns 23,551 shares of the company’s stock, valued at approximately $6,125,850.61. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. In other news, CEO Gary S. Guthart sold 27,385 shares of the stock in a transaction dated Thursday, October 26th. The shares were sold at an average price of $260.11, for a total value of $7,123,112.35. Following the completion of the sale, the chief executive officer now owns 23,551 shares in the company, valued at $6,125,850.61. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director Amy L. Ladd sold 500 shares of the stock in a transaction dated Thursday, September 14th. The shares were sold at an average price of $305.68, for a total transaction of $152,840.00. Following the completion of the sale, the director now owns 702 shares of the company’s stock, valued at approximately $214,587.36. The disclosure for this sale can be found here. Insiders sold a total of 55,208 shares of company stock worth $15,275,529 over the last quarter. 0.90% of the stock is currently owned by corporate insiders.

Intuitive Surgical Trading Up 0.4 %

NASDAQ ISRG traded up $1.33 on Friday, hitting $305.28. 2,993,483 shares of the company were exchanged, compared to its average volume of 1,772,118. Intuitive Surgical, Inc. has a 12 month low of $222.65 and a 12 month high of $358.07. The company has a market cap of $107.48 billion, a PE ratio of 71.83, a PEG ratio of 4.85 and a beta of 1.31. The stock has a fifty day moving average of $284.26 and a 200-day moving average of $305.09.

Intuitive Surgical (NASDAQ:ISRG) last issued its earnings results on Thursday, October 19th. The medical equipment provider reported $1.46 EPS for the quarter, beating the consensus estimate of $1.40 by $0.06. Intuitive Surgical had a return on equity of 12.91% and a net margin of 22.14%. The company had revenue of $1.74 billion during the quarter, compared to the consensus estimate of $1.77 billion. During the same period last year, the business posted $0.90 EPS. The firm’s revenue for the quarter was up 12.0% compared to the same quarter last year. On average, analysts expect that Intuitive Surgical, Inc. will post 4.54 earnings per share for the current year.

Intuitive Surgical Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System to enable complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.